Clinical Trial Update: UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study of UF-KURE-BCMA CAR-T Cells in relapsed or refractory multiple myeloma, with the study currently not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• UF-KURE-BCMA CAR-T Cells

Snippet

Sponsor: David Wald | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Status: NOT_YET_RECRUITING